Results 271 to 280 of about 6,661,076 (287)

Microbiology and risk factors for gram-positive Cocci bacteremia in biliary infections

Hepatobiliary and Pancreatic Diseases International, 2020
Yeon-Ji Kim, Ik Hyun Jo, Woo-Chul Chung
exaly  

Antibiotics for treatment of resistant gram-positive coccal infections

Indian Journal of Pediatrics, 2006
Nahed Abdel-Haq, Basim I Asmar
exaly  

A Systems Biological Approach Reveals Multiple Crosstalk Mechanism between Gram-Positive and Negative Bacterial Infections: An Insight into Core Mechanism and Unique Molecular Signatures

PLoS ONE, 2014
SHIEK SSJ Ahmed
exaly  

Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.

Clinical Infectious Diseases, 2015
Greg Moeck, G Ralph Corey
exaly  

Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials

International Journal of Antimicrobial Agents, 2010
exaly  

Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: Results from a multicenter trial

Clinical Therapeutics, 2003
Jim Z Li, Richard Willke, Brian E Rittenhouse   +2 more
exaly  

Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014–16)

Journal of Antimicrobial Chemotherapy, 2018
Helio S Sader, Rodrigo Mendes, Mariana Castanheira   +2 more
exaly  

METHODS FOR TREATING GRAM POSITIVE BACTERIAL INFECTION

2019
PEYSSONNAUX CAROLE, MATHIEU JACQUES, MALERBA MARIANGELA   +2 more
openaire   +2 more sources

[Treatment of resistant Gram-positive bacterial infections].

Medecine et maladies infectieuses, 2012
openaire   +1 more source

Development of DNA polymerase IIIC inhibitors for the treatment of Gram-positive bacterial infections

Expert Opinion on Therapeutic Patents, 2005
exaly